This new approval for SeQuent builds on the recent approvals of Tulazzin® (Tulathromycin) and Halofusol® (Halofuginone) in Europe. All these approvals have been received within 12 months of filing, which reflects on SeQuent's growing strengths in introducing new products for the regulated markets.

Citramox® is the first generic version of Vetrimoxin LA (Innovator: Ceva Animal Health Inc) to be approved and launched in Europe, which is an effective antibiotic indicated for the treatment of respiratory infections caused by Mannheimia haemolytica and Pasteurella multocida susceptible to amoxicillin in cattle and pigs. Citramox® formulation has good homogeneity and high fluidity profile, which along with its user-friendly plastic vial packaging and withdrawal times offers superior value to farmers.

The market size in Europe for Amoxicillin Long-Acting products is estimated to be ~€ 20 Million.